MAY 15 2026
Genentech — Tecentriq (atezolizumab) $RHHBY
for muscle-invasive bladder cancer
FDA approved Genentech's Tecentriq for adjuvant treatment of muscle-invasive bladder cancer using ctDNA-guided therapy.
About
Bladder cancer occurs when abnormal cells grow uncontrollably in the bladder, often spreading to other organs and typically first detected through blood in the urine. Tecentriq (atezolizumab) is an immunotherapy that helps the immune system recognize and attack cancer cells by blocking a protein that tumors use to hide. By unmasking these cancer cells, the drug may reduce the risk of recurrence in high-risk patients after bladder removal surgery.
Pivotal trial
This is a global Phase III, randomized, placebo-controlled, double-blind study designed to evaluate the efficacy and safety of adjuvant treatment with atezolizumab compared with placebo in participants with MIBC who are circulating tumour deoxyribonucleic acid (ctDNA) positive and are at high risk for recurrence following cystectomy.
Source: ClinicalTrials.gov
Also in development
Drug Watch — recent news on Tecentriq
- Brussels gives green light to Zepzelca alongside Tecentriq for advanced small cell lung cancer - Demócrata
- Roche's Tecentriq Wins FDA Nod for Label Expansion in Bladder Cancer - Yahoo Finance
- What is Tecentriq SC? This new 7-minute cancer shot is making treatment faster for patients - theweek.in
- Genentech gains bladder cancer indication for Tecentriq - MSN
- FDA clears Roche's Tecentriq, paired with ctDNA test, for bladder cancer - FirstWord Pharma